

Second Opinion: Investigators Provide Perspectives on the Current and Future Use of Novel Therapies for Non-Hodgkin Lymphoma**THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.**

- 1. In the Phase III SUNMO study, which of the following regimens demonstrated a significant improvement in median progression-free survival (PFS) in comparison to rituximab with gemcitabine/oxaliplatin (R-GemOx) for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who were not eligible for transplant?**
 - Glofitamab with polatuzumab vedotin
 - Epcoritamab with gemcitabine/oxaliplatin (GemOx)
 - Mosunetuzumab with polatuzumab vedotin**
 - Odronextamab with GemOx
 - None of the above
- 2. In the LOTIS-7 study evaluating the combination of glofitamab and loncastuximab tesirine for R/R non-Hodgkin lymphoma, what was the approximate overall response rate across all dose levels?**
 - 29%
 - 40%
 - 62%
 - 93%**
- 3. Recent findings from the Phase III frontMIND study evaluating the addition of tafasitamab/lenalidomide to R-CHOP for newly diagnosed, high-risk DLBCL include which of the following results?**
 - A numerical but nonsignificant improvement in PFS
 - A statistically significant improvement in PFS with no new safety signals**
 - A statistically significant improvement in PFS but an increased risk of secondary hematologic cancer
- 4. The Phase III POLARGO study evaluating polatuzumab vedotin with R-GemOx versus R-GemOx alone for patients with R/R DLBCL reported which major efficacy outcome with the polatuzumab vedotin combination?**
 - A numerical but nonsignificant improvement in PFS
 - A significant improvement in PFS, with overall survival (OS) not reported
 - A significant improvement in PFS and a numerical but nonsignificant improvement in OS
 - A significant improvement in both PFS and OS**
- 5. Which of the following adverse events is the most commonly reported among patients with DLBCL receiving tafasitamab?**
 - Cytokine release syndrome
 - Cytopenia**
 - Peripheral edema
 - Ocular events